Navigation Links
NanoBio Awarded U.S. Patent for RSV Vaccine
Date:12/19/2016

ANN ARBOR, Mich., Dec. 19, 2016 /PRNewswire/ -- NanoBio Corporation today announced the issuance of U.S. Patent No. 9,492,525 Human Respiratory Syncytial Virus (RSV) Vaccine. The patent broadly covers the composition of NanoBio's intramuscular and intranasal RSV vaccine candidates, which combine the company's innovative nanoemulsion (NE) adjuvant with strain L19 of RSV. Additional patent applications covering the combination of the NE adjuvant with other strains of RSV and with RSV F protein are currently being pursued.

"This critical patent strengthens NanoBio's position as we prepare to advance our NE RSV vaccine into clinical studies," said Dr. Ali Fattom, Senior Vice President of Vaccine Research and Development, NanoBio. "Based on our research to date, the use of whole inactivated RSV L19 in combination with our NE adjuvant elicits robust protection across multiple strains of RSV in both cotton rats and non-human primates, without evidence of safety concerns or the enhancement of disease observed with prior formalin-inactivated vaccines."

Formulation of RSV L19 virus with NanoBio's NE adjuvant splits and fully inactivates the virus as a result of the adjuvant's inherent antimicrobial properties, yet the immunogenicity of L19's native viral proteins is preserved. The resulting NE RSV vaccine incorporates all of the viral epitopes-including F, G and other proteins-enabling a potentially much broader immune response than what is elicited by subunit vaccine candidates.

About RSV

Respiratory syncytial virus, commonly referred to as RSV, is a highly contagious viral disease and is one of the most common causes of bronchiolitis and pneumonia. Up to 2.5 million infections occur in the U.S. each year. It is the number one cause of childhood hospitalization globally. Nearly all children are infected with the virus at least once by the age of two to three years, and many develop pulmonary disease and/or asthma that persists throughout adult life, making them susceptible to re-infection. The disease is particularly dangerous for premature babies, children with preexisting health conditions and the elderly. RSV is responsible for 16,000 deaths each year in adults older than 65. Currently, there are no approved vaccines for RSV.

About NanoBio

Headquartered in Ann Arbor, Michigan, NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing vaccines and anti-infective treatments derived from its patented NanoStat® technology platform. The company's NanoStat® vaccine technology employs a novel oil-in-water nanoemulsion (NE) that can incorporate, deliver and adjuvant multiple antigen types. The NE adjuvant is effective when administered via intranasal or intramuscular vaccination. When applied intranasally, NE vaccines elicit both mucosal and systemic immunity.

NanoBio is currently developing NE vaccines for several respiratory and sexually transmitted diseases, including RSV, pertussis, pandemic influenza, anthrax, and prophylactic and therapeutic HSV2.

For more information on NanoBio or its products, please visit www.nanobio.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nanobio-awarded-us-patent-for-rsv-vaccine-300381040.html


'/>"/>
SOURCE NanoBio Corporation
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. Global Nanobiotechnology Report 2015-2025 - Focus on Applications, Markets and Companies with Profiles of 250+ Companies - Research and Markets
2. Global Nanobiotechnology Report 2016 - Applications, Markets and Companies Analysis to 2025 -- Research and Markets
3. Global Nanobiotechnology Report 2016-2025 - Profiles of 248 Companies with their 180 Collaborations
4. Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024
5. Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies
6. Global Nanobiotechnology Report 2015 - Applications, Markets and Companies Forecasts to 2024
7. NanoBio To Present Data At ICAAC Supporting The Development Of Safe And Effective RSV & Herpes Simplex Virus-2 Vaccines
8. SRI Awarded $150 Million NIAID-DAIDS Contract to Provide Development and Manufacturing Support for Promising HIV-Prevention Products
9. Salk Institute awarded $25 million grant from Helmsley Charitable Trust
10. Lajollacooks4u Awarded TripAdvisor’s 2016 Certificate of Excellence
11. Worcester Polytechnic Institute Team Awarded Patent for Reprogramming Skin Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... business process optimization firm for the life sciences and healthcare industries, announces a ... in San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” ...
(Date:10/9/2017)... Arizona (PRWEB) , ... October 09, 2017 , ... ... Kindred, a four-tiered line of medical marijuana products targeting the needs of consumers ... and packaging of Kindred takes place in Phoenix, Arizona. , As operators of ...
Breaking Biology Technology:
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/5/2017)... YORK , April 5, 2017 Today ... is announcing that the server component of the HYPR ... known for providing the end-to-end security architecture that empowers ... HYPR has already secured over 15 million ... makers including manufacturers of connected home product suites and ...
(Date:3/30/2017)...  On April 6-7, 2017, Sequencing.com will host the ... hackathon at Microsoft,s headquarters in Redmond, Washington ... developing health and wellness apps that provide a unique, ... is the first hackathon for personal genomics and ... in the genomics, tech and health industries are sending ...
Breaking Biology News(10 mins):